VRC07-523LS
Phase 2Biologic
VRC07-523LS is an experimental antibody treatment being studied to prevent HIV infection in people at high risk of exposure to the virus.[1] VRC07-523LS is currently being investigated across 3 indications[3], with its most advanced program in Phase 2.[1]
VRC07-523LS is one of 96 biologic programs targeting AIDS. It is currently in Phase 2.
3
Indications
20
Total Trials
11
Active Trials
95
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
326 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Hivid
CConrado Roberto Hoffmann Filho
Phase 3
Betaseron
BayerPhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
TWINRIX™
GSKPhase 3
F/TAF
GileadPhase 3
F/TDF
GileadPhase 3
PTM SEMA
GileadPhase 3
Interleukin 2
EEssen Biotech
Phase 3
Motexafin Gadolinium
PPharmacyclics LLC.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Intravenous3 trials
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03928821·27 enrolled
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04212091·33 enrolled
Treatment2 trials
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02140255·1,120 enrolled
Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption
Active, not recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04340596·118 enrolled
HIV-12 trials
A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1
Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT07390955·83 enrolled
Monoclonal1 trial
Concentration1 trial
11 more indications
Infants1 trial
Immunogenicity1 trial
Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
Active, not recruiting·—·Phase 1/2·NCT04983030·36 enrolled
Combination Therapy1 trial
HIV infection1 trial
Vaccination1 trial
RV630 - Approach to Control HIV With Immune Enhancement and Vaccination (ACHIEV
Recruiting·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 1·NCT06484335·48 enrolled
Safety and Efficacy1 trial
Adult1 trial
Bispecific Antibody1 trial
HIV-1 infection1 trial
A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Not yet recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06987318·40 enrolled
Clinical Trial1 trial
Unspecified1 trial
The Tatelo Plus Study
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT06508749·41 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for VRC07-523LS. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details